Suzano S.A. (SUZ): what the price assumes

boothcheck covers Suzano S.A. (SUZ) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-07-11.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/SUZ

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 11: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage (computed at the 7% minimum rate; the CAPM rate 5.1% sits below it).

Reconcile: at the x-ray's 9.3% required return this reads ~3.5%/yr; the models below use their own rates.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

The price is supported by asset-based and earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 3.9%); the inversion above states its own rate.

Per-Model Detail (n=15)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• Suzano sells hardwood pulp at a 21.2% trailing operating margin, yet at $8.07 the stock trades below where every family of valuation method lands, from asset value to forward cash flow.
• The discount has a reason: $14.8 billion of net debt against $2.1 billion of trailing operating income, with interest coverage at just 1.5 times, leaves the equity as a thin slice on a heavily levered commodity balance sheet.
• Watch the newly closed Arbex tissue joint venture with Kimberly-Clark (51% stake, $1.3 billion, closed July 1, 2026) and whether the next quarterly print shows the reaffirmed cash-cost reduction actually arriving.

Bull Case

Start with what management just did with the balance sheet, because it is the loudest signal in the story. Carrying $14.8 billion of net debt, Suzano still wrote a $1.3 billion check on July 1 for a 51% stake in Kimberly-Clark's international tissue assets, now renamed Arbex. A management team worried about its own solvency does not volunteer for that. The confidence rests on cash generation that is easy to miss behind the leverage headline: operating cash generation ran R$2.5 billion in the first quarter alone, and trailing free cash flow of roughly $2.7 billion covers a meaningful slice of the debt stack every year the pulp market cooperates. S&P moved its outlook to positive on the deal, framing an upgrade path if leverage holds near 3 times through the cycle, which is the rating agency's way of saying the debt is large but the machine servicing it is credible.

The operating engine itself is running, not merely surviving. Suzano moved 2.84 million tons of pulp in the first quarter, almost 200,000 tons more than a year earlier, at an average export price of $562 per ton, and management reaffirmed that 2026 cash costs will come in below 2025 levels. Volume growth plus falling unit costs is the combination a commodity producer wants heading into any price environment, because it widens the gap between Suzano's cost position and the marginal producer who sets the price. The tissue venture extends the same logic downstream: converting the company's own pulp into branded consumer product dampens the earnings swing that pure market-pulp sellers absorb in full.

Then there is the price itself. Every family of method points the same direction: asset-based approaches land roughly 40% above today's quote, earnings-power and peer-multiple reads sit about a third above it, and even the forward cash-flow methods, usually the demanding ones, come out ahead of the market price. A business earning a 21.2% operating margin priced below its book-value-plus-profitability read is the market charging a fear premium for leverage. If deleveraging proceeds on the path S&P sketched, that fear premium is the return.

Bear Case

The structural truth a holder has to sit with is this: Suzano is cheap because the equity is a leveraged claim on a commodity price nobody controls. Net debt of $14.8 billion stands against $2.1 billion of trailing operating income, roughly 7 times on a pre-tax basis, and interest coverage is 1.5 times. That last number deserves a slow read. It means operating income covers interest expense with a margin of error of about half, so a moderate downswing in pulp prices does not merely dent earnings, it starts consuming the cushion that keeps creditors patient. Liquid assets of $3.0 billion against $17.7 billion of gross debt frame how little of the obligation could be met from cash on hand.

The market is already pricing distress-adjacent caution: today's quote sits below what even a sustained 5% annual decline in operating profit would warrant on standard assumptions. The bear case is that the discount is earned rather than mistaken. The first quarter showed the mechanism in miniature: pulp prices up just 1% year over year, the paper and packaging unit's EBITDA down 8%, and Brazilian real appreciation eating into the margin of a company whose costs are in reais and whose revenue is in dollars. When the currency and the commodity move against a 1.5-times-covered balance sheet at the same time, equity holders absorb the swing at both ends.

And management chose this moment to add more. The Arbex venture arrived with roughly $1.0 billion of net debt raised to finance the transaction, layered on top of the existing stack. Diversification into tissue may eventually smooth the cycle, but integration of a multi-country consumer business is a new execution risk for a company whose competence is growing eucalyptus and running mills. The street's median stance is a Hold at $11, which reads less like conviction in the upside than an acknowledgment that the price cannot be trusted until the leverage math improves.

Valuation

Today's price pays about 12 times company-wide operating income, a multiple low enough that it sits below what even a 5% annual decline in operating profit would warrant. The market is not paying for growth here; it is charging admission to the risk. That framing matters because the methods themselves are unusually united. Asset-value approaches (book value plus the 17.6% trailing return on equity the company earns on it) land roughly 40% above the price. Earnings-power reads and peer multiples sit about a third above it. Even the forward-looking cash-flow methods, which reach their numbers by holding today's EV/EBITDA multiple flat over a five-year horizon, come out above the market price. When every family clears the price, the question stops being whether the stock is expensive and becomes why the market discounts it anyway.

The answer lives in the solvency picture. Net debt of $14.8 billion runs about 7 times trailing operating income on a pre-tax basis, interest coverage is 1.5 times, and gross debt of $17.7 billion dwarfs the $3.0 billion of liquid assets. The company is not burning cash, and first-quarter operating cash generation of R$2.5 billion shows the servicing capacity is real, but a balance sheet built this way converts ordinary commodity-price volatility into outsized equity volatility. The one number to hold onto: a 21.2% trailing operating margin funds the whole structure, and the price is a bet on whether that margin, at these debt levels, survives the pulp cycle intact.

Catalysts

The Arbex joint venture is the nearest concrete event already in motion. Suzano closed the $1.3 billion purchase of a 51% stake in Kimberly-Clark's international tissue business on July 1, 2026, with the venture carrying roughly $1.0 billion of net debt from deal financing. The next several quarters will show whether the tissue assets contribute earnings that justify the added leverage, and S&P has framed the stakes explicitly: its positive outlook contemplates an upgrade if Suzano holds leverage at about 3 times or below through the cycle. A rating upgrade would directly lower the cost of carrying the company's largest liability.

The operating calendar centers on the next quarterly report. First-quarter results, presented April 30, showed adjusted EBITDA of R$4.6 billion, pulp volumes up nearly 200,000 tons year over year, and management guiding second-quarter sales and prices higher, particularly in Western markets, while reaffirming that 2026 cash costs will land below 2025. The items to check against that guidance: whether export pulp pricing improved from the $562 per ton first-quarter average, whether the paper and packaging unit arrested its 8% EBITDA decline, and how much Brazilian real strength continued to compress dollar margins. Sell-side positioning is neutral, with the most recent rating a Hold at an $11 target, leaving room for estimate revisions in either direction as the JV consolidates into reported numbers.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• CE (CELANESE CORPORATION)
• FY2025 10-K: …as well as the manner in which the information is used internally by the Company's chief operating decision maker ("CODM"), who is the Company's President and Chief Executive Officer. The Company's CODM regularly reviews the Operating profit of each reportable segment to assess financial results and allocate…
• FY2025 10-K: …Engineered Materials business segment. The Company manages its Acetyl Chain business segment by leveraging its ability to sell chemicals externally to end-use markets or downstream to its acetate tow, intermediate chemistry, emulsion polymers, redispersible powders and ethylene vinyl acetate polymers businesses.…
• PKG (PACKAGING CORP OF AMERICA)
• FY2025 10-K: …manufacturing operations to customers and load size. Our corrugated manufacturing operations typically serve customers within a 150-mile radius. Customers We sell containerboard and corrugated products to approximately 12,000 customers in approximately 27,000 locations. About 70% of our corrugated products sales are…
• FY2025 10-K: …under its revolving credit facility, $1,241 million in liquidity. 1 Net income excluding special items, earnings per diluted share excluding special items, and segment EBITDA excluding special items are non-GAAP financial measures. See "Non-GAAP Financial Measures" later in this item 7. 20 Packaging segment operating…
• AVY (AVERY DENNISON CORPORATION)
• FY2025 10-K: …foreign jurisdictions, partially offset by higher tax charges from valuation allowances. Refer to Note 14, "Taxes Based on Income," to the Consolidated Financial Statements for more information. RESULTS OF OPERATIONS BY REPORTABLE SEGMENT Our CODM uses segment adjusted operating income to evaluate segment performance…
• FY2025 10-K: …global economic conditions, tariffs, geopolitical uncertainty, and changes in environmental standards, regulations and preferences; (ii) competitors' actions, including pricing, expansion in key markets, and product offerings; (iii) the cost and availability of raw materials; (iv) the degree to which higher costs can…
• IFF (INTERNATIONAL FLAVORS & FRAGRANCES INC)
• FY2025 10-K: . These factors are beyond our control and could negatively impact our results of operations. Additionally, a significant portion of our sales comes from a relatively small number of large multinational customers. In 2025, our 25 largest customers, a majority of which were multinational consumer products companies,…
• FY2025 10-K: …as well as regulatory trends may impact demand for our products, which may have a negative effect on our operating results and future growth. • Our business is highly competitive, and if we are unable to compete effectively our sales and results of operations will suffer. • If we are unable to successfully execute…
• EMN (EASTMAN CHEMICAL CO)
• FY2025 10-K: …divested businesses, non-operational sites and product lines, and discontinued programs. (6) Segment assets include accounts receivable, inventory, fixed assets, goodwill, and intangible assets. 109 Table of Contents NOTES TO THE AUDITED CONSOLIDATED FINANCIAL STATEMENTS For year ended December 31, 2023 (Dollars in…
• FY2025 10-K: …expenses, other components of post-employment (benefit) cost, net, and other (income) charges, net. (2) Other is not considered an operating segment. Other includes sales and costs from growth initiatives and businesses, R&D costs, pension and other postretirement benefit plans income (expense), net, and other income…
• WLK (Westlake Corporation)
• FY2025 10-K: …rates and lower margins. Moreover, profitability in the petrochemical industry is affected by the worldwide level of demand along with vigorous price competition which may intensify due to, among other things, new industry capacity. In general, weak economic conditions reduce demand and put pressure on margins. It is…
• FY2025 10-K: …and the revocation thereof by domestic or foreign authorities could adversely affect our ability to compete in global markets. 13 Table of Contents We sell most of our commodity products in highly competitive markets and face significant competition and price pressure. We sell most of our commodity products in highly…
• GPK (Graphic Packaging Holding Co)
• FY2025 10-K: …customer functions. The Company is organized to bring the full resources of its global and local innovation, design and manufacturing capabilities to all of its customers with the goal of delivering packaging solutions that are more circular, more functional and more convenient. The Company competes with a wide range…
• FY2025 10-K: …customers include GlaxoSmithKline, Bayer, Johnson & Johnson, Abbott, Novartis, L'Oréal S.A., Procter & Gamble and Colgate-Palmolive. The Company also sells paperboard in the open market to independent and integrated paperboard packaging producers. Sales of the Company's principal products are primarily accomplished…
• PX (PX)
• (no filing in the citation store)

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.